Rocket’s gene therapy candidate, Kresladi, to treat severe leukocyte adhesion deficiency-I (LAD-I) is being considered under priority review with a June 30 decision date. Rocket also plans to submit another biologics license application (BLA) in the first half of the year for RP-L102 treatment for fanconi anemia.
“For Rocket we focused from day one starting the company to do something for the rare disease patient and community before we have therapies in the clinic,” said Rocket president and chief operating officer Kinnari Patel.
Along with the Empire State Building in New York, where Rocket has offices, the FDA headquarters, Niagara Falls, and NASDAQ are among the more than 100 places around the world that will light up in the green, blue, pink and purple colors that represent rare disease. Rocket first began the illumination campaign in 2019, although the National Organization for Rare Disease (NORD) took over more recently.
Meanwhile, Rocket also is planning a day of panel discussions and events on Thursday, as well as a media push, to draw attention to rare diseases, which in total affect 10% of people in the US. Themes for the day center on patient support, patient advocacy and genetic testing, Patel said.
https://endpts.com/rocket-pharma-lights-up-buildings-again-for-rare-disease-day-as-it-awaits-first-fda-decision/
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Pfizer’s New Gene Therapy BEQVEZ™ Wins FDA Approval for Hemophilia B
In a notable advancement for hemophilia treatment, Pfizer Inc. (NYSE: PFE) has received U.S. Food and Drug Administration approval for BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy aimed at adults suffering from moderate to severe hemophilia B. This...
Astellas Teams Up with Poseida Therapeutics for Innovative CAR-T Cell Therapy Development
Astellas Pharma, through its subsidiary Xyphos Biosciences, has entered into a second collaborative agreement with Poseida Therapeutics to pioneer the development of off-the-shelf cell therapies for solid tumors. This follows their initial partnership in 2023, which...
Cytiva Introduces New Cell Manufacturing Lines for Viral Vectors
Viral vector-based gene therapies hold immense promise for treating a multitude of diseases. However, their widespread adoption has been hindered by inefficient manufacturing methods and the absence of established standardized processes, resulting in high costs and...
Top 10 Best-Selling Cell and Gene Therapies
When it comes to cell and gene therapy revenues, it’s feast or famine. The feast side is well covered in this A-List, which ranks the top 10 therapies according to sales figures from 2023. The famine side begins almost exactly where this A-List ends. Future A-Lists...
Related Services
Plasmids GMP Services
AAV GMP Services
